2 S&P 500 Stocks with Solid Fundamentals and 1 We Find Risky
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execut…
Yahoo Finance
Updated Jun 2, 2026
Upgrade to a paid plan to see AI rating history on the chart.
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execut…
- Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX’s PROBODY® and Regeneron's Veloci-…
The anti-aging biotech has secured one of the year’s biggest venture fundings to bring its first drug into testing. Elsewhere, Lilly nabbed a “GLP-2” obesity d…
Investors need to pay close attention to REGN stock based on the movements in the options market lately.
The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a winne…
<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxNTmJFMHlEMVFrVnNjNnZ3bTZLS3ZpYmJMRzREOXBJNU5lcHNveFNrS085eDVTLU8tYjh5ODNmRV9SZ0xXbWZUNHpmcjhMdmhMX…
Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Regeneron Pharmaceuticals has underperformed the Dow Jones over the past year, and analysts remain moderately optimistic about the stock’s outlook.
Not investment advice. Past performance does not guarantee future results. Full disclaimer